{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T05:51:37Z","timestamp":1780552297016,"version":"3.54.1"},"reference-count":107,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CRR"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:sec><jats:title>:<\/jats:title><jats:p>Nowadays, tumor necrosis factor-alpha (TNF\u03b1) inhibitors have revolutionised the treatment of inflammatory arthritides by demonstrating efficacy with an acceptable toxicity profile. However, autoimmune phenomena and clinical entities have been reported ranging from an isolated presence of autoantibodies to full-blown autoimmune diseases, including drug-induced lupus (DIL).<\/jats:p><\/jats:sec><jats:sec><jats:title>Case Presentation:<\/jats:title><jats:p>A 62-year-old woman with rheumatoid arthritis (RA) refractory to methotrexate and prednisone was treated with adalimumab (ADA). 4 months later, she presented acute cutaneous eruptions after sun exposure, positive ANA (1\/640 fine speckled pattern), Ro (SSA) and anti- Smith (Sm) antibodies with no other clinical or laboratory abnormalities. The diagnosis of DIL was made, ADA was discontinued, and she was treated successfully with prednisone plus local calcineurin inhibitors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>Thus, we review the literature for cases of DIL development in patients treated with TNF\u03b1 inhibitors. Rheumatologists should be aware of the possible adverse events and the requirement of careful clinical evaluation and monitoring.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1573397117666211102094330","type":"journal-article","created":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T04:01:55Z","timestamp":1635912115000},"page":"72-82","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["TNF-induced Lupus. A Case-Based Review"],"prefix":"10.2174","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4104-2878","authenticated-orcid":true,"given":"Anastasia","family":"Skalkou","sequence":"first","affiliation":[{"name":"Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina 45110, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9383-5722","authenticated-orcid":true,"given":"Eleftherios","family":"Pelechas","sequence":"additional","affiliation":[{"name":"Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina 45110, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5193-2284","authenticated-orcid":true,"given":"Paraskevi V.","family":"Voulgari","sequence":"additional","affiliation":[{"name":"Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina 45110, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2232-0326","authenticated-orcid":true,"given":"Alexandros A.","family":"Drosos","sequence":"additional","affiliation":[{"name":"Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina 45110, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/nrrheum.2013.168","volume":"10","author":"Burmester G.R.","year":"2014","unstructured":"Burmester G.R.; Feist E.; D\u00f6rner T.; Emerging cell and cytokine targets in rheumatoid arthritis. Nat Rev Rheumatol 2014,10(2),77-88","journal-title":"Nat Rev Rheumatol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/1741-7015-11-88","volume":"11","author":"Rosman Z.","year":"2013","unstructured":"Rosman Z.; Shoenfeld Y.; Zandman-Goddard G.; Biologic therapy for autoimmune diseases: an update. BMC Med 2013,11,88","journal-title":"BMC Med"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/nrrheum.2014.123","volume":"10","author":"Boyman O.","year":"2014","unstructured":"Boyman O.; Comte D.; Spertini F.; Adverse reactions to biologic agents and their medical management. Nat Rev Rheumatol 2014,10(10),612-627","journal-title":"Nat Rev Rheumatol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jaci.2015.10.023","volume":"137","author":"Her M.","year":"2016","unstructured":"Her M.; Kavanaugh A.; Alterations in immune function with biologic therapies for autoimmune disease. J Allergy Clin Immunol 2016,137(1),19-27","journal-title":"J Allergy Clin Immunol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/j.jaad.2009.04.048","volume":"62","author":"Ahdout J.","year":"2010","unstructured":"Ahdout J.; Haley J.C.; Chiu M.W.; Erythema multiforme during anti-tumor necrosis factor treatment for plaque psoriasis. J Am Acad Dermatol 2010,62(5),874-879","journal-title":"J Am Acad Dermatol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1136\/ard.2007.075663","volume":"67","author":"Voulgari P.V.","year":"2008","unstructured":"Voulgari P.V.; Markatseli T.E.; Exarchou S.A.; Zioga A.; Drosos A.A.; Granuloma annulare induced by anti-tumour necrosis factor therapy. Ann Rheum Dis 2008,67(4),567-570","journal-title":"Ann Rheum Dis"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s00296-018-4212-0","volume":"39","author":"Pelechas E.","year":"2019","unstructured":"Pelechas E.; Papoudou-Bai A.; Voulgari P.V.; Drosos A.A.; Granuloma annulare development in a patient with rheumatoid arthritis treated with tocilizumab: case-based review. Rheumatol Int 2019,39(2),353-357","journal-title":"Rheumatol Int"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1080\/03009740902922612","volume":"38","author":"Exarchou S.A.","year":"2009","unstructured":"Exarchou S.A.; Voulgari P.V.; Markatseli T.E.; Zioga A.; Drosos A.A.; Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors. Scand J Rheumatol 2009,38(5),328-331","journal-title":"Scand J Rheumatol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1136\/ard.2004.024182","volume":"64","author":"Eriksson C.","year":"2005","unstructured":"Eriksson C.; Engstrand S.; Sundqvist K-G.; Rantap\u00e4\u00e4-Dahlqvist S.; Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Ann Rheum Dis 2005,64(3),403-407","journal-title":"Ann Rheum Dis"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1093\/rheumatology\/kep080","volume":"48","author":"Williams E.L.","year":"2009","unstructured":"Williams E.L.; Gadola S.; Edwards C.J.; Anti-TNF-induced lupus. Rheumatology (Oxford) 2009,48(7),716-720","journal-title":"Rheumatology (Oxford)"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1097\/MD.0b013e3181441a68","volume":"86","author":"Ramos-Casals M.","year":"2007","unstructured":"Ramos-Casals M.; Brito-Zer\u00f3n P.; Mu\u00f1oz S.; Soria N.; Galiana D.; Bertolaccini L.; Cuadrado M.J.; Khamashta M.A.; Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007,86(4),242-251","journal-title":"Medicine (Baltimore)"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"Aletaha D.","year":"2010","unstructured":"Aletaha D.; Neogi T.; Silman A.J.; Funovits J.; Felson D.T.; Bingham C.O.; Birnbaum N.S.; Burmester G.R.; Bykerk V.P.; Cohen M.D.; Combe B.; Costenbader K.H.; Dougados M.; Emery P.; Ferraccioli G.; Hazes J.M.; Hobbs K.; Huizinga T.W.; Kavanaugh A.; Kay J.; Kvien T.K.; Laing T.; Mease P.; M\u00e9nard H.A.; Moreland L.W.; Naden R.L.; Pincus T.; Smolen J.S.; Stanislawska-Biernat E.; Symmons D.; Tak P.P.; Upchurch K.S.; Vencovsk\u00fd J.; Wolfe F.; Hawker G.; 2010 rheumatoid arthritis classification criteria: an american college of rheumatology\/european league against rheumatism collaborative initiative. Arthritis Rheum 2010,62(9),2569-2581","journal-title":"Arthritis Rheum"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1002\/art.40930","volume":"71","author":"Aringer M.","year":"2019","unstructured":"Aringer M.; Costenbader K.; Daikh D.; Brinks R.; Mosca M.; Ramsey-Goldman R.; Smolen J.S.; Wofsy D.; Boumpas D.T.; Kamen D.L.; Jayne D.; Cervera R.; Costedoat-Chalumeau N.; Diamond B.; Gladman D.D.; Hahn B.; Hiepe F.; Jacobsen S.; Khanna D.; Lerstr\u00f8m K.; Massarotti E.; McCune J.; Ruiz-Irastorza G.; Sanchez-Guerrero J.; Schneider M.; Urowitz M.; Bertsias G.; Hoyer B.F.; Leuchten N.; Tani C.; Tedeschi S.K.; Touma Z.; Schmajuk G.; Anic B.; Assan F.; Chan T.M.; Clarke A.E.; Crow M.K.; Czirj\u00e1k L.; Doria A.; Graninger W.; Halda-Kiss B.; Hasni S.; Izmirly P.M.; Jung M.; Kum\u00e1novics G.; Mariette X.; Padjen I.; Pego-Reigosa J.M.; Romero-Diaz J.; R\u00faa-Figueroa Fern\u00e1ndez \u00cd.; Seror R.; Stummvoll G.H.; Tanaka Y.; Tektonidou M.G.; Vasconcelos C.; Vital E.M.; Wallace D.J.; Yavuz S.; Meroni P.L.; Fritzler M.J.; Naden R.; D\u00f6rner T.; Johnson S.R.; 2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol 2019,71(9),1400-1412","journal-title":"Arthritis Rheumatol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"634","DOI":"10.7326\/0003-4819-131-8-199910190-00031","volume":"131","author":"Brion P.H.","year":"1999","unstructured":"Brion P.H.; Mittal-Henkle A.; Kalunian K.C.; Autoimmune skin rashes associated with etanercept for rheumatoid arthritis. Ann Intern Med 1999,131(8),634","journal-title":"Ann Intern Med"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/S0016-5085(99)70332-X","volume":"117","author":"Rutgeerts P.","year":"1999","unstructured":"Rutgeerts P.; D\u2019Haens G.; Targan S.; Vasiliauskas E.; Hanauer S.B.; Present D.H.; Mayer L.; Van Hogezand R.A.; Braakman T.; DeWoody K.L.; Schaible T.F.; Van Deventer S.J.; Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn\u2019s disease. Gastroenterology 1999,117(4),761-769","journal-title":"Gastroenterology"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1002\/1529-0131(200011)43:11<2383::AID-ANR2>3.0.CO;2-D","volume":"43","author":"Charles P.J.","year":"2000","unstructured":"Charles P.J.; Smeenk R.J.; De Jong J.; Feldmann M.; Maini R.N.; Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000,43(11),2383-2390","journal-title":"Arthritis Rheum"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1093\/rheumatology\/40.11.1317","volume":"40","author":"Bleumink G.S.","year":"2001","unstructured":"Bleumink G.S.; ter Borg E.J.; Ramselaar C.G.; Stricker B.H.; Etanercept-induced subacute cutaneous lupus erythematosus. Rheumatology (Oxford) 2001,40(11),1317-1319","journal-title":"Rheumatology (Oxford)"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1136\/ard.61.11.1031","volume":"61","author":"Cairns A.P.","year":"2002","unstructured":"Cairns A.P.; Duncan M.K.; Hinder A.E.; Taggart A.J.; New onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis. Ann Rheum Dis 2002,61(11),1031-1032","journal-title":"Ann Rheum Dis"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/S0140-6736(02)07714-0","volume":"359","author":"Shakoor N.","year":"2002","unstructured":"Shakoor N.; Michalska M.; Harris C.A.; Block J.A.; Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002,359(9306),579-580","journal-title":"Lancet"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"625","DOI":"10.7326\/0003-4819-137-7-200210010-00030","volume":"137","author":"Ali Y.","year":"2002","unstructured":"Ali Y.; Shah S.; Infliximab-induced systemic lupus erythematosus. Ann Intern Med 2002,137(7),625-626","journal-title":"Ann Intern Med"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1191\/0961203302lu236cr","volume":"11","author":"Favalli E.G.","year":"2002","unstructured":"Favalli E.G.; Sinigaglia L.; Varenna M.; Arnoldi C.; Drug-induced lupus following treatment with infliximab in rheumatoid arthritis. Lupus 2002,11(11),753-755","journal-title":"Lupus"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s10067-002-0654-5","volume":"22","author":"Debandt M.","year":"2003","unstructured":"Debandt M.; Vittecoq O.; Descamps V.; Le Lo\u00ebt X.; Meyer O.; Anti-TNF-alpha-induced systemic lupus syndrome. Clin Rheumatol 2003,22(1),56-61","journal-title":"Clin Rheumatol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1097\/00054725-200305000-00005","volume":"9","author":"Klapman J.B.","year":"2003","unstructured":"Klapman J.B.; Ene-Stroescu D.; Becker M.A.; Hanauer S.B.; A lupus-like syndrome associated with infliximab therapy. Inflamm Bowel Dis 2003,9(3),176-178","journal-title":"Inflamm Bowel Dis"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1046\/j.1365-2230.2003.01411.x","volume":"28","author":"Swale V.J.","year":"2003","unstructured":"Swale V.J.; Perrett C.M.; Denton C.P.; Black C.M.; Rustin M.H.; Etanercept-induced systemic lupus erythematosus. Clin Exp Dermatol 2003,28(6),604-607","journal-title":"Clin Exp Dermatol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1002\/art.11033","volume":"48","author":"Carlson E.","year":"2003","unstructured":"Carlson E.; Rothfield N.; Etanercept-induced lupus-like syndrome in a patient with rheumatoid arthritis. Arthritis Rheum 2003,48(4),1165-1166","journal-title":"Arthritis Rheum"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"ii30","DOI":"10.1136\/ard.62.suppl_2.ii30","volume":"62","author":"Flendrie M.","year":"2003","unstructured":"Flendrie M.; Creemers M.C.; Welsing P.M.; den Broeder A.A.; van Riel P.L.; Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis. Ann Rheum Dis 2003,62(Suppl. 2),ii30-ii33","journal-title":"Ann Rheum Dis"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/S1590-8658(03)00448-1","volume":"35","author":"Sarzi-Puttini P.","year":"2003","unstructured":"Sarzi-Puttini P.; Ardizzone S.; Manzionna G.; Atzeni F.; Colombo E.; Antivalle M.; Carrabba M.; Bianchi-Porro G.; Infliximab-induced lupus in Crohn\u2019s disease: a case report. Dig Liver Dis 2003,35(11),814-817","journal-title":"Dig Liver Dis"},{"key":"ref=28","first-page":"2725","volume":"30","author":"Christopher-Stine L.","year":"2003","unstructured":"Christopher-Stine L.; Wigley F.; Tumor necrosis factor-alpha antagonists induce lupus-like syndrome in patients with scleroderma overlap\/mixed connective tissue disease. J Rheumatol 2003,30(12),2725-2727","journal-title":"J Rheumatol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1111\/j.1479-8077.2004.00090.x","volume":"7","author":"Russo P.","year":"2004","unstructured":"Russo P.; Tymms K.; Smith G.; Infliximab-induced systemic lupus erythematosus. APLAR J Rheumatol 2004,7,130-132","journal-title":"APLAR J Rheumatol"},{"key":"ref=30","first-page":"S141","volume":"22","author":"Cush J.J.","year":"2004","unstructured":"Cush J.J.; Unusual toxicities with TNF inhibition: heart failure and drug-induced lupus. Clin Exp Rheumatol 2004,22(5)(Suppl. 35),S141-S147","journal-title":"Clin Exp Rheumatol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/j.1365-2230.2004.01471.x","volume":"29","author":"Stratigos A.J.","year":"2004","unstructured":"Stratigos A.J.; Antoniou C.; Stamathioudaki S.; Avgerinou G.; Tsega A.; Katsambas A.D.; Discoid lupus erythematosus-like eruption induced by infliximab. Clin Exp Dermatol 2004,29(2),150-153","journal-title":"Clin Exp Dermatol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1053\/j.gastro.2003.10.047","volume":"126","author":"Colombel J.F.","year":"2004","unstructured":"Colombel J.F.; Loftus E.V.; Tremaine W.J.; Egan L.J.; Harmsen W.S.; Schleck C.D.; Zinsmeister A.R.; Sandborn W.J.; The safety profile of infliximab in patients with Crohn\u2019s disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004,126(1),19-31","journal-title":"Gastroenterology"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"R545","DOI":"10.1186\/ar1715","volume":"7","author":"De Bandt M.","year":"2005","unstructured":"De Bandt M.; Sibilia J.; Le Lo\u00ebt X.; Prouzeau S.; Fautrel B.; Marcelli C.; Boucquillard E.; Siame J.L.; Mariette X.; Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther Club Rhumatismes et Inflammation2005,7(3),R545-R551","journal-title":"Arthritis Res Ther"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"R666","DOI":"10.1186\/ar1724","volume":"7","author":"Flendrie M.","year":"2005","unstructured":"Flendrie M.; Vissers W.H.; Creemers M.C.; de Jong E.M.; van de Kerkhof P.C.; van Riel P.L.; Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther 2005,7(3),R666-R676","journal-title":"Arthritis Res Ther"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/S0151-9638(05)79281-4","volume":"132","author":"Vabre-Latre C.M.","year":"2005","unstructured":"Vabre-Latre C.M.; Bayle P.; Marguery M.C.; Gadroy A.; Durand D.; Bazex J.; [Worsening of subacute lupus erythematosus induced by infliximab]. Ann Dermatol Venereol [in French].2005,132(4),349-353","journal-title":"Ann Dermatol Venereol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/01.rhu.0000152148.55133.ba","volume":"11","author":"Benucci M.","year":"2005","unstructured":"Benucci M.; Li Gobbi F.; Fossi F.; Manfredi M.; Del Rosso A.; Drug-induced lupus after treatment with infliximab in rheumatoid arthritis. J Clin Rheumatol 2005,11(1),47-49","journal-title":"J Clin Rheumatol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1093\/ndt\/gfh832","volume":"20","author":"Stokes M.B.","year":"2005","unstructured":"Stokes M.B.; Foster K.; Markowitz G.S.; Ebrahimi F.; Hines W.; Kaufman D.; Moore B.; Wolde D.; D\u2019Agati V.D.; Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant 2005,20(7),1400-1406","journal-title":"Nephrol Dial Transplant"},{"key":"ref=38","first-page":"760","volume":"32","author":"Richez C.","year":"2005","unstructured":"Richez C.; Dumoulin C.; Schaeverbeke T.; Infliximab induced chilblain lupus in a patient with rheumatoid arthritis. J Rheumatol 2005,32(4),760-761","journal-title":"J Rheumatol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"E5","DOI":"10.1016\/S0190-9622(03)00869-7","volume":"52","author":"High W.A.","year":"2005","unstructured":"High W.A.; Muldrow M.E.; Fitzpatrick J.E.; Cutaneous lupus erythematosus induced by infliximab. J Am Acad Dermatol 2005,52(4),E5","journal-title":"J Am Acad Dermatol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1097\/01.MIB.0000186408.07769.78","volume":"11","author":"Nancey S.","year":"2005","unstructured":"Nancey S.; Blanvillain E.; Parmentier B.; Flouri\u00e9 B.; Bayet C.; Bienvenu J.; Fabien N.; Infliximab treatment does not induce organ-specific or nonorgan-specific autoantibodies other than antinuclear and anti-double-stranded DNA autoantibodies in Crohn\u2019s disease. Inflamm Bowel Dis 2005,11(11),986-991","journal-title":"Inflamm Bowel Dis"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1080\/08916930400021378","volume":"38","author":"Elkayam O.","year":"2005","unstructured":"Elkayam O.; Burke M.; Vardinon N.; Zakut V.; Yitzhak R.B.; Paran D.; Levartovsky D.; Litinsky I.; Caspi D.; Autoantibodies profile of rheumatoid arthritis patients during treatment with infliximab. Autoimmunity 2005,38(2),155-160","journal-title":"Autoimmunity"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"946","DOI":"10.3346\/jkms.2006.21.5.946","volume":"21","author":"Kang M.J.","year":"2006","unstructured":"Kang M.J.; Lee Y.H.; Lee J.; Etanercept-induced systemic lupus erythematosus in a patient with rheumatoid arthritis. J Korean Med Sci 2006,21(5),946-949","journal-title":"J Korean Med Sci"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2174\/157488606777934495","volume":"1","author":"Rajakulendran S.","year":"2006","unstructured":"Rajakulendran S.; Deighton C.; Adverse dermatological reactions in rheumatoid arthritis patients treated with etanercept, an anti-TNFalpha drug. Curr Drug Saf 2006,1(3),259-264","journal-title":"Curr Drug Saf"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1001\/archderm.142.1.115","volume":"142","author":"Schneider S.W.","year":"2006","unstructured":"Schneider S.W.; Staender S.; Schl\u00fcter B.; Luger T.A.; Bonsmann G.; Infliximab-induced lupus erythematosus tumidus in a patient with rheumatoid arthritis. Arch Dermatol 2006,142(1),115-116","journal-title":"Arch Dermatol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1093\/rheumatology\/kel227","volume":"45","author":"van Rijthoven A.W.","year":"2006","unstructured":"van Rijthoven A.W.; Bijlsma J.W.; Canninga-van Dijk M.; Derksen R.H.; van Roon J.A.; Onset of systemic lupus erythematosus after conversion of infliximab to adalimumab treatment in rheumatoid arthritis with a pre-existing anti-dsDNA antibody level. Rheumatology (Oxford) 2006,45(10),1317-1319","journal-title":"Rheumatology (Oxford)"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1093\/rheumatology\/kei220","volume":"45","author":"P\u00e9rez-Garc\u00eda C.","year":"2006","unstructured":"P\u00e9rez-Garc\u00eda C.; Maymo J.; Lisbona P\u00e9rez M.P.; Almirall Bernab\u00e9 M.; Carbonell Abell\u00f3 J.; Drug-induced systemic lupus erythematosus in ankylosing spondylitis associated with infliximab. Rheumatology (Oxford) 2006,45(1),114-116","journal-title":"Rheumatology (Oxford)"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.ejim.2006.02.010","volume":"17","author":"Pataka A.","year":"2006","unstructured":"Pataka A.; Tzouvelekis A.; Bouros D.; Infliximab-induced non-specific interstitial pneumonia and lupus-like eruption. Eur J Intern Med 2006,17(7),520","journal-title":"Eur J Intern Med"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1093\/rheumatology\/kei227","volume":"45","author":"Pallotta P.","year":"2006","unstructured":"Pallotta P.; Cianchini G.; Ruffelli M.; Puddu P.; Infliximab-induced lupus-like reaction in a patient with psoriatic arthritis. Rheumatology (Oxford) 2006,45(1),116-117","journal-title":"Rheumatology (Oxford)"},{"key":"ref=49","first-page":"24","volume":"33","author":"Comby E.","year":"2006","unstructured":"Comby E.; Tanaff P.; Mariotte D.; Costentin-Pignol V.; Marcelli C.; Ballet J.J.; Evolution of antinuclear antibodies and clinical patterns in patients with active rheumatoid arthritis with longterm infliximab therapy. J Rheumatol 2006,33(1),24-30","journal-title":"J Rheumatol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1002\/art.21702","volume":"55","author":"Chadha T.","year":"2006","unstructured":"Chadha T.; Hernandez J.E.; Infliximab-related lupus and associated valvulitis: a case report and review of the literature. Arthritis Rheum 2006,55(1),163-166","journal-title":"Arthritis Rheum"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1007\/s00063-007-1104-6","volume":"102","author":"Haake H.","year":"2007","unstructured":"Haake H.; K\u00f6neke J.; Amann K.; vom Dahl J.; Janssen U.; Development of systemic lupus erythematosus with focal proliferative lupus nephritis during anti-TNF-alpha therapy for psoriatic arthritis. Med Klin (Munich) 2007,102(10),852-857","journal-title":"Med Klin (Munich)"},{"key":"ref=52","first-page":"61","volume":"60","author":"Portuesi M.G.","year":"2008","unstructured":"Portuesi M.G.; Perosa P.; Neprhrotic syndrome in a patient with rheumatoid arthritis treated with adalimumab: a case report. Reumatismo 2008,60(1),61-63","journal-title":"Reumatismo"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1378\/chest.08-0034","volume":"134","author":"Abunasser J.","year":"2008","unstructured":"Abunasser J.; Forouhar F.A.; Metersky M.L.; Etanercept-induced lupus erythematosus presenting as a unilateral pleural effusion. Chest 2008,134(4),850-853","journal-title":"Chest"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1016\/j.transproceed.2008.03.102","volume":"40","author":"Page A.V.","year":"2008","unstructured":"Page A.V.; Liles W.C.; Tumor necrosis factor-alpha inhibitor-induced lupus-like syndrome presenting as fever of unknown origin in a liver transplant recipient: case report and concise review of the literature. Transplant Proc 2008,40(5),1768-1770","journal-title":"Transplant Proc"},{"key":"ref=55","first-page":"1116","volume":"26","author":"Mounach A.","year":"2008","unstructured":"Mounach A.; Ghazi M.; Nouijai A.; Ghozlani I.; Achemlal L.; Bezza A.; El Maghraoui A.; Drug-induced lupus-like syndrome in ankylosing spondylitis treated with infliximab. Clin Exp Rheumatol 2008,26(6),1116-1118","journal-title":"Clin Exp Rheumatol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.semarthrit.2007.08.003","volume":"37","author":"Costa M.F.","year":"2008","unstructured":"Costa M.F.; Said N.R.; Zimmermann B.; Drug-induced lupus due to anti-tumor necrosis factor alpha agents. Semin Arthritis Rheum 2008,37(6),381-387","journal-title":"Semin Arthritis Rheum"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1177\/0961203308093922","volume":"18","author":"Kocharla L.","year":"2009","unstructured":"Kocharla L.; Mongey A.B.; Is the development of drug-related lupus a contraindication for switching from one TNF alpha inhibitor to another? Lupus 2009,18(2),169-171","journal-title":"Lupus"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/S0025-6196(11)60668-X","volume":"84","author":"Wetter D.A.","year":"2009","unstructured":"Wetter D.A.; Davis M.D.; Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic. Mayo Clin Proc 2009,84(11),979-984","journal-title":"Mayo Clin Proc"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1007\/s00105-008-1699-4","volume":"60","author":"Sohl S.","year":"2009","unstructured":"Sohl S.; Renner R.; Winter U.; Bodendorf M.; Paasch U.; Simon J.C.; Treudler R.; Drug-induced lupus erythematosus tumidus during treatment with adalimumab. Hautarzt 2009,60(10),826-829","journal-title":"Hautarzt"},{"key":"ref=60","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.nephro.2010.05.003","volume":"6","author":"Sacqu\u00e9p\u00e9e M.","year":"2010","unstructured":"Sacqu\u00e9p\u00e9e M.; Rouleau V.; Cantin J.F.; Quirin N.; Doussy Y.; Val\u00e9ry J.C.; Picu C.; Tivollier J.M.; Active WHO class IV lupus nephritis in a patient treated with etanercept for a psoriasic arthritis. Nephrol Ther 2010,6(6),537-540","journal-title":"Nephrol Ther"},{"key":"ref=61","first-page":"201","volume":"20","author":"Vannucchi V.","year":"2011","unstructured":"Vannucchi V.; Grazzini M.; Pieralli F.; Giannotta M.; Biagioni C.; Nozzoli C.; Adalimumab-induced lupus erythematosus with central nervous system involvement in a patient with Crohn\u2019s disease. J Gastrointestin Liver Dis 2011,20(2),201-203","journal-title":"J Gastrointestin Liver Dis"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"696285","DOI":"10.1155\/2011\/696285","volume":"2011","author":"Chatziralli I.P.","year":"2011","unstructured":"Chatziralli I.P.; Kanonidou E.; Chatzirallis A.; Dimitriadis P.; Keryttopoulos P.; Episcleritis related to drug-induced lupus erythematosus following infliximab therapy: a case report. Case Rep Med 2011,2011,696285","journal-title":"Case Rep Med"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.2169\/internalmedicine.50.5430","volume":"50","author":"Araki D.","year":"2011","unstructured":"Araki D.; Fujii H.; Matsumura M.; Yamagishi M.; Yachie A.; Kawano M.; Etanercept-induced lupus accompanied by hemophagocytic syndrome. Intern Med 2011,50(17),1843-1848","journal-title":"Intern Med"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.3899\/jrheum.100830","volume":"38","author":"Ye C.","year":"2011","unstructured":"Ye C.; Sholter D.; Martin L.; Keeling S.; Successful switch of patients with rheumatoid arthritis developing anti-tumor necrosis factor (anti-TNF)-induced lupus to another anti-TNF agent. J Rheumatol 2011,38(6),1216","journal-title":"J Rheumatol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/j.1365-4632.2011.04871.x","volume":"50","author":"Williams V.L.","year":"2011","unstructured":"Williams V.L.; Cohen P.R.; TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists. Int J Dermatol 2011,50(5),619-625","journal-title":"Int J Dermatol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"3315","DOI":"10.1007\/s00296-011-2137-y","volume":"32","author":"Diaz J.C.","year":"2012","unstructured":"Diaz J.C.; Vallejo S.; Ca\u00f1as C.A.; Drug-induced lupus in anti-TNF-alpha therapy and its treatment with rituximab. Rheumatol Int 2012,32(10),3315-3317","journal-title":"Rheumatol Int"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.1007\/s00296-011-2016-6","volume":"32","author":"Guerin M.","year":"2012","unstructured":"Guerin M.; Haettich B.; Bara C.; Artru L.; Prophette B.; C\u00e9l\u00e9rier P.; Maillard H.; Lupus attributable to anti-TNF therapy and revealed by interstitial granulomatous dermatitis. Rheumatol Int 2012,32(9),2937-2940","journal-title":"Rheumatol Int"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/j.1600-0560.2012.01894.x","volume":"39","author":"Hawryluk E.B.","year":"2012","unstructured":"Hawryluk E.B.; Linskey K.R.; Duncan L.M.; Nazarian R.M.; Broad range of adverse cutaneous eruptions in patients on TNF-alpha antagonists. J Cutan Pathol 2012,39(5),481-492","journal-title":"J Cutan Pathol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s00296-012-2617-8","volume":"34","author":"Akg\u00fcl \u00d6.","year":"2014","unstructured":"Akg\u00fcl \u00d6.; K\u0131l\u0131\u00e7 G.; K\u0131l\u0131\u00e7 E.; C\u00fcce \u0130.; \u00d6zg\u00f6\u00e7men S.; A patient with ankylosing spondylitis who developed infliximab-induced lupus and treated with etanercept. Rheumatol Int 2014,34(3),443-444","journal-title":"Rheumatol Int"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s10067-011-1924-x","volume":"31","author":"Sifuentes Giraldo W.A.","year":"2012","unstructured":"Sifuentes Giraldo W.A.; Ahij\u00f3n Lana M.; Garc\u00eda Villanueva M.J.; Gonz\u00e1lez Garc\u00eda C.; V\u00e1zquez Diaz M.; Chilblain lupus induced by TNF-\u03b1 antagonists: a case report and literature review. Clin Rheumatol 2012,31(3),563-568","journal-title":"Clin Rheumatol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3109\/08923973.2013.780077","volume":"35","author":"Lis-\u015awi\u0119ty A.","year":"2013","unstructured":"Lis-\u015awi\u0119ty A.; Brzezi\u0144ska-Wcis\u0142o L.; Widuchowska M.; Kucharz E.; Subacute cutaneous lupus erythematosus in the course of rheumatoid arthritis: a relationship with TNF-\u03b1 antagonists and rituximab therapy? Immunopharmacol Immunotoxicol 2013,35(3),443-446","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1177\/0961203313479423","volume":"22","author":"Cemil B.C.","year":"2013","unstructured":"Cemil B.C.; Atas H.; Canpolat F.; Akca Y.; Sasmaz R.; Infliximab-induced discoid lupus erythematosus. Lupus 2013,22(5),515-518","journal-title":"Lupus"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/j.crohns.2012.06.016","volume":"7","author":"Farkas K.","year":"2013","unstructured":"Farkas K.; Nagy F.; Kov\u00e1cs L.; Wittmann T.; Moln\u00e1r T.; Anti-tumor necrosis factor-\u03b1 induced systemic lupus erythematosus in a patient with metastatic Crohn\u2019s disease--what is the role of anti-TNF antibody? J Crohn\u2019s Colitis 2013,7(4),e143-e145","journal-title":"J Crohn\u2019s Colitis"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1007\/s10067-013-2361-9","volume":"32","author":"Santiago T.","year":"2013","unstructured":"Santiago T.; Santiago M.G.; Rovisco J.; Duarte C.; Malcata A.; da Silva J.A.; A case of infliximab-induced lupus in a patient with ankylosing spondylitis: is it safe switch to another anti-TNF-\u03b1 agent? Clin Rheumatol 2013,32(12),1819-1822","journal-title":"Clin Rheumatol"},{"key":"ref=75","first-page":"447","volume":"43","author":"Yahya T.M.","year":"2013","unstructured":"Yahya T.M.; Dhanyamraju S.; Harrington T.M.; Prichard J.W.; Spontaneous resolution of lupus nephritis following withdrawal of etanercept. Ann Clin Lab Sci 2013,43(4),447-449","journal-title":"Ann Clin Lab Sci"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1590\/abd1806-4841.20153893","volume":"90","author":"Quaresma M.V.","year":"2015","unstructured":"Quaresma M.V.; Bernardes Filho F.; Oliveira F.B.; Pockstaller M.P.; Dias M.F.; Azulay D.R.; Anti-TNF-\u03b1 and hydralazine drug-induced lupus An Bras Dermatol 2015,90(3)(Suppl. 1),125-129","journal-title":"An Bras Dermatol"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1177\/0961203313517153","volume":"23","author":"Brunasso A.M.","year":"2014","unstructured":"Brunasso A.M.; Aberer W.; Massone C.; Subacute lupus erythematosus during treatment with golimumab for seronegative rheumatoid arthritis. Lupus 2014,23(2),201-203","journal-title":"Lupus"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"285","DOI":"10.12865\/CHSJ.40.04.11","volume":"40","author":"Lupu A.","year":"2014","unstructured":"Lupu A.; Tieranu C.; Constantinescu C.L.; Diculescu M.; TNF\u03b1 inhibitor induced lupus-like syndrome (TAILS) in a patient with IBD. Curr Health Sci J 2014,40(4),285-288","journal-title":"Curr Health Sci J"},{"key":"ref=79","first-page":"740","volume":"32","author":"Mor A.","year":"2005","unstructured":"Mor A.; Bingham C.O.; Barisoni L.; Lydon E.; Belmont H.M.; Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept. J Rheumatol 2005,32(4),740-743","journal-title":"J Rheumatol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"bcr2014207323","DOI":"10.1136\/bcr-2014-207323","volume":"2015","author":"Kelly D.","year":"2015","unstructured":"Kelly D.; O\u2019Connell O.; Henry M.; Adalimumab-induced lupus serositis. BMJ Case Rep 2015,2015,bcr2014207323","journal-title":"BMJ Case Rep"},{"key":"ref=81","first-page":"13030\/qt18r2916d","volume":"21","author":"Lieberman MR","year":"2014","unstructured":"Lieberman MR; Liebman TN; Alapati U; Khachemoune A; TNF-inhibitor induced lupus in a patient treated with adalimumab for rheumatoid arthritis. Dermatol Online J 2014,21(2),13030\/qt18r2916d","journal-title":"Dermatol Online J"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.revmed.2015.04.003","volume":"36","author":"Barreau M.","year":"2015","unstructured":"Barreau M.; Pontoizeau J.; Courtheoux F.; Comoz F.; Leport Y.; Verneuil L.; Dompmartin A.; [Cutaneous lesions in a woman treated with adalimumab]. Rev Med Interne [in French].2015,36(12),862-864","journal-title":"Rev Med Interne"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"e140","DOI":"10.1111\/pde.12576","volume":"32","author":"West E.S.","year":"2015","unstructured":"West E.S.; Nanda K.; Ofodile O.; Rutledge J.; Brandling-Bennett H.A.; Adalimumab-Induced Cutaneous Lupus Erythematosus in a 16-Year-Old Girl with Juvenile Idiopathic Arthritis. Pediatr Dermatol 2015,32(4),e140-e144","journal-title":"Pediatr Dermatol"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1080\/00325481.2017.1249266","volume":"129","author":"Mudduluru B.M.","year":"2017","unstructured":"Mudduluru B.M.; Shah S.; Shamah S.; Swaminath A.; TNF-alpha antagonist induced lupus on three different agents. Postgrad Med 2017,129(2),304-306","journal-title":"Postgrad Med"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/jcpt.12506","volume":"42","author":"Lomicov\u00e1 I.","year":"2017","unstructured":"Lomicov\u00e1 I.; Such\u00fd D.; Pizinger K.; Cetkovsk\u00e1 P.; A case of lupus-like syndrome in a patient receiving adalimumab and a brief review of the literature on drug-induced lupus erythematosus. J Clin Pharm Ther 2017,42(3),363-366","journal-title":"J Clin Pharm Ther"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s10067-017-3884-2","volume":"37","author":"Shovman O.","year":"2018","unstructured":"Shovman O.; Tamar S.; Amital H.; Watad A.; Shoenfeld Y.; Diverse patterns of anti-TNF-\u03b1-induced lupus: case series and review of the literature. Clin Rheumatol 2018,37(2),563-568","journal-title":"Clin Rheumatol"},{"key":"ref=87","first-page":"169","volume":"16","author":"Haimovic A.","year":"2017","unstructured":"Haimovic A.; Kamino H.; Cohen D.E.; Annular elastolytic giant cell granuloma successfully treated with adalimumab subsequently complicated by drug-induced lupus. J Drugs Dermatol 2017,16(2),169-171","journal-title":"J Drugs Dermatol"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"bcr-2017-223473","DOI":"10.1136\/bcr-2017-223473","volume":"2018","author":"Stein J.E.","year":"2018","unstructured":"Stein J.E.; Patterson-Fortin J.; Bodnar B.E.; Anti-TNF therapy-induced lupus erythematosus-like syndrome in a patient treated with adalimumab for cutaneous psoriasis. BMJ Case Rep 2018,2018,bcr-2017-223473","journal-title":"BMJ Case Rep"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1111\/ijd.14674","volume":"59","author":"Turk D.","year":"2020","unstructured":"Turk D.; Vellaichamy G.; Lyons A.B.; Parks-Miller A.; Nelson T.; Meysami A.; Hamzavi I.H.; Anti-tumor necrosis factor (TNF)-induced lupus in a patient with hidradenitis suppurativa. Int J Dermatol 2020,59(3),e73-e74","journal-title":"Int J Dermatol"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.jdcr.2019.01.015","volume":"5","author":"Tierney E.","year":"2019","unstructured":"Tierney E.; Kirthi S.; Ramsay B.; Ahmad K.; Ustekinumab-induced subacute cutaneous lupus. JAAD Case Rep 2019,5(3),271-273","journal-title":"JAAD Case Rep"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"e314","DOI":"10.1111\/1346-8138.14884","volume":"46","author":"Urata Y.","year":"2019","unstructured":"Urata Y.; Honda T.; Kaku Y.; Kabashima K.; Chilblain lupus during treatment with golimumab for rheumatoid arthritis. J Dermatol 2019,46(9),e314-e315","journal-title":"J Dermatol"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s40268-020-00320-5","volume":"20","author":"Bolton C","year":"2020","unstructured":"Bolton C; Chen Y; Hawthorn R; Schepel I R.M; Harriss E; Hofmann SC; Ellis S; 22 September 2020. Drugs R D 2020,20,319-330","journal-title":"Drugs R D"},{"key":"ref=93","first-page":"2503","volume":"34","author":"Bout-Tabaku S.","year":"2007","unstructured":"Bout-Tabaku S.; Rivas-Chacon R.; Restrepo R.; Systemic lupus erythematosus in a patient treated with etanercept for polyarticular juvenile rheumatoid arthritis. J Rheumatol 2007,34(12),2503-2504","journal-title":"J Rheumatol"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.2169\/internalmedicine.4646-20","volume":"59","author":"Yoshikawa N.","year":"2020","unstructured":"Yoshikawa N.; Matsubara E.; Yamamoto M.; Yamazaki H.; Uehara M.; Kamata M.; Tanaka H.; Drug-induced bullous pemphigoid and lupus erythematosus occurring under anti-TNF-\u03b1 and IL-6 therapy in a patient with rheumatoid arthritis. Intern Med 2020,59(20),2611-2618","journal-title":"Intern Med"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"1756284821997794","DOI":"10.1177\/1756284821997794","volume":"14","author":"Choi S.J.","year":"2021","unstructured":"Choi S.J.; Ahn S.M.; Oh J.S.; Hong S.; Lee C-K.; Yoo B.; Ye B.D.; Yang S.K.; Park S.H.; Kim Y.G.; Anti-tumor necrosis factor-induced lupus in patients with inflammatory bowel disease: a hospital-based cohort study from Korea. Therap Adv Gastroenterol 2021,14,1756284821997794","journal-title":"Therap Adv Gastroenterol"},{"key":"ref=96","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1590\/S0482-50042013000400008","volume":"53","author":"Vaz J.L.","year":"2013","unstructured":"Vaz J.L.; Andrade C.A.; Pereira A.C.; Martins Mde.F.; Levy R.A.; Systematic review of infliximab-induced autoantibodies and systemic lupus erythematosus. Rev Bras Reumatol [in English, Portuguese].2013,53(4),358-364","journal-title":"Rev Bras Reumatol"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/ibd.21362","volume":"17","author":"Beigel F.","year":"2011","unstructured":"Beigel F.; Schnitzler F.; Paul Laubender R.; Pfennig S.; Weidinger M.; G\u00f6ke B.; Seiderer J.; Ochsenk\u00fchn T.; Brand S.; Formation of antinuclear and double-strand DNA antibodies and frequency of lupus-like syndrome in anti-TNF-\u03b1 antibody-treated patients with inflammatory bowel disease. Inflamm Bowel Dis 2011,17(1),91-98","journal-title":"Inflamm Bowel Dis"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1136\/ard.2005.043166","volume":"65","author":"Schiff M.H.","year":"2006","unstructured":"Schiff M.H.; Burmester G.R.; Kent J.D.; Pangan A.L.; Kupper H.; Fitzpatrick S.B.; Donovan C.; Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 2006,65(7),889-894","journal-title":"Ann Rheum Dis"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.autrev.2009.10.003","volume":"9","author":"Ramos-Casals M.","year":"2010","unstructured":"Ramos-Casals M.; Roberto-Perez-Alvarez ; Diaz-Lagares C.; Cuadrado M.J.; Khamashta M.A.; Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun Rev BIOGEAS Study Group2010,9(3),188-193","journal-title":"Autoimmun Rev"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1196\/annals.1422.019","volume":"1108","author":"Borchers A.T.","year":"2007","unstructured":"Borchers A.T.; Keen C.L.; Gershwin M.E.; Drug-induced lupus. Ann N Y Acad Sci 2007,1108,166-182","journal-title":"Ann N Y Acad Sci"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s13075-019-2028-2","volume":"21","author":"De Bandt M.","year":"2019","unstructured":"De Bandt M.; Anti-TNF-alpha-induced lupus. Arthritis Res Ther 2019,21(1),235","journal-title":"Arthritis Res Ther"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/j.1365-2796.2003.01298.x","volume":"255","author":"D\u2019Auria F.","year":"2004","unstructured":"D\u2019Auria F.; Rovere-Querini P.; Giazzon M.; Ajello P.; Baldissera E.; Manfredi A.A.; Sabbadini M.G.; Accumulation of plasma nucleosomes upon treatment with anti-tumour necrosis factor-alpha antibodies. J Intern Med 2004,255(3),409-418","journal-title":"J Intern Med"},{"key":"ref=103","doi-asserted-by":"crossref","first-page":"919","DOI":"10.4049\/jimmunol.159.2.919","volume":"159","author":"Hart S.P.","year":"1997","unstructured":"Hart S.P.; Dougherty G.J.; Haslett C.; Dransfield I.; CD44 regulates phagocytosis of apoptotic neutrophil granulocytes, but not apoptotic lymphocytes, by human macrophages. J Immunol 1997,159(2),919-925","journal-title":"J Immunol"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2174\/1874312901206010315","volume":"6","author":"Almoallim H.","year":"2012","unstructured":"Almoallim H.; Al-Ghamdi Y.; Almaghrabi H.; Alyasi O.; Anti-Tumor Necrosis Factor-\u03b1 Induced Systemic Lupus Erythematosus(). Open Rheumatol J 2012,6,315-319","journal-title":"Open Rheumatol J"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S0140-6736(13)60954-X","volume":"382","author":"Wahren-Herlenius M.","year":"2013","unstructured":"Wahren-Herlenius M.; D\u00f6rner T.; Immunopathogenic mechanisms of systemic autoimmune disease. Lancet 2013,382(9894),819-831","journal-title":"Lancet"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"J266","DOI":"10.1016\/j.jaut.2009.11.012","volume":"34","author":"Chang C.","year":"2010","unstructured":"Chang C.; Gershwin M.E.; Drugs and autoimmunity--a contemporary review and mechanistic approach. J Autoimmun 2010,34(3),J266-J275","journal-title":"J Autoimmun"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"357","DOI":"10.2165\/11588500-000000000-00000","volume":"34","author":"Chang C.","year":"2011","unstructured":"Chang C.; Gershwin M.E.; Drug-induced lupus erythematosus: incidence, management and prevention. Drug Saf 2011,34(5),357-374","journal-title":"Drug Saf"}],"container-title":["Current Rheumatology Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573397117666211102094330","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/197543\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573397117666211102094330","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T10:45:18Z","timestamp":1673693118000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/197543\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":107,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573397117666211102094330","relation":{},"ISSN":["1573-3971"],"issn-type":[{"value":"1573-3971","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-10-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-30","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}